Q1 2025 Beigene Ltd Earnings Call Transcript

May 7, 2025 / 12:00 PM GMT

Release Date Price: €208 (-6.31%)

Transcript 10-Q8-K

Key Points

Positve

BeiGene Ltd (ONC) achieved GAAP profitability for the first time in Q1 2025, marking a significant financial milestone.
The company reported a 49% increase in revenue year-over-year, reaching $1.1 billion in Q1 2025.
Brukinsa, a BTK inhibitor, became the market leader in the US by revenue, surpassing competitors and demonstrating strong growth.
BeiGene Ltd (ONC) has a robust pipeline with over 10 proof of concept readouts expected across its solid tumor portfolio in 2025.
The company has expanded its global reach, treating over 1.7 million cancer patients and achieving significant sales growth in Europe and other international markets.

Negative

The company faces challenges in navigating an increasingly complex global environment, including pricing pressures and trade policy uncertainties.
There is potential risk associated with the IRA negotiations and the impact on pricing, particularly for Calquence starting in 2026.
The company is still in the early stages of commercialization in some international markets, which may impact immediate revenue growth.
BeiGene Ltd (ONC) is investing heavily in R&D, which could strain financial resources if expected outcomes are not achieved.
The competitive landscape in the BCL-2 inhibitor market is limited, with only a few key players, which could impact market penetration and growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

688235.SS - Beigene Ltd
Q1 2025 Beigene Ltd Earnings Call
May 07, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone. Welcome to Beijing's Q1 2025 earnings call webcast.

All lines have been placed on mute to prevent any background noise.

After the speaker's remarks, there will be a question and answer session.

At this time, I would like to turn the call over to the company.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello and welcome. Thanks for joining us today. I'm Dan Mallor, head of investor relations at Beijing.

Before we begin, please note that you can find additional materials, including a replay of today's webcast and presentation on the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.